New oral pill aims to clear psoriasis in major trial

NCT ID NCT07672561

Recruiting now Disease control Sponsor: Zhejiang Wenda Pharma Technology LTD. Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This phase 3 study tests whether the experimental drug WD-890 can safely improve skin clearance in adults with moderate to severe plaque psoriasis. Participants are randomly assigned to receive either WD-890 or a placebo tablet daily for up to 52 weeks. The main goals are to see if more people achieve clear or almost clear skin and at least a 75% reduction in psoriasis severity by week 16.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: WD-890
What this could lead to: If successful, WD-890 could offer a new oral treatment option for people with moderate to severe plaque psoriasis, potentially improving skin clearance and quality of life.
What could go wrong: This is a phase 3 trial, but results may not confirm efficacy or safety. The drug could cause side effects or fail to outperform placebo. Long-term risks are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MODERATE TO SEVERE PLAQUE PSORIASIS

Contacts and locations

Locations

Hospital of Dermatology, Chinese Academy of Medical Sciences
RECRUITING

Nanjing, Jiangsu, 210042, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.